The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds - PubMed (original) (raw)
The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds
J Rømer et al. J Invest Dermatol. 1994 Apr.
Free article
Abstract
Expression of urokinase-type plasminogen activator receptor mRNA was examined in vivo in mouse skin wounds by in situ hybridization. Urokinase-type plasminogen activator receptor mRNA was found in keratinocytes at the front of the regenerative epithelial outgrowths at the edge of 12-, 48-, and 96-hour-old wounds. The signal was strongest in the keratinocytes just beginning to move 12 h after wounding. At later time-points the signal was weaker, but still confined to keratinocytes at the wound edges. Using in situ hybridization, no cells expressing urokinase-type plasminogen activator receptor mRNA could be detected in normal epidermis, in normal-looking epidermis adjacent to the wounds, in dermis, in subcutis, or in newly formed granulation tissue. The specificity of the results was supported by the use of antisense RNA from two different non-overlapping cDNA clones and the corresponding sense RNA probes, and by Northern analysis of tissue extracts. Together with previous findings on expression of urokinase-type plasminogen activator and its type 1 inhibitor, the localized and regulated expression of urokinase-type plasminogen activator receptor mRNA during skin wound healing indicates that focal extracellular proteolysis at the cell surface generated by receptor-bound urokinase-type plasminogen activator is implicated in the migration of re-epithelializing keratinocytes.
Similar articles
- Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds.
Rømer J, Lund LR, Eriksen J, Ralfkiaer E, Zeheb R, Gelehrter TD, Danø K, Kristensen P. Rømer J, et al. J Invest Dermatol. 1991 Nov;97(5):803-11. doi: 10.1111/1523-1747.ep12486833. J Invest Dermatol. 1991. PMID: 1919045 - Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin.
Rømer J, Pyke C, Lund LR, Ralfkiaer E, Danø K. Rømer J, et al. J Invest Dermatol. 2001 Mar;116(3):353-8. doi: 10.1046/j.1523-1747.2001.01241.x. J Invest Dermatol. 2001. PMID: 11231307 - Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester.
Lund LR, Eriksen J, Ralfkiaer E, Rømer J. Lund LR, et al. J Invest Dermatol. 1996 Apr;106(4):622-30. doi: 10.1111/1523-1747.ep12345425. J Invest Dermatol. 1996. PMID: 8617995 - Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M, Vaheri A, Virolainen S, Saarialho-Kere U, Jahkola T, Sirén V. Weckroth M, et al. Br J Dermatol. 2004 Dec;151(6):1189-96. doi: 10.1111/j.1365-2133.2004.06261.x. Br J Dermatol. 2004. PMID: 15606514 - Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Nozaki S, Endo Y, Nakahara H, Yoshizawa K, Ohara T, Yamamoto E. Nozaki S, et al. Anticancer Drugs. 2006 Nov;17(10):1109-17. doi: 10.1097/01.cad.0000231483.09439.3a. Anticancer Drugs. 2006. PMID: 17075310 Review.
Cited by
- Urokinase-type plasminogen activator promotes N-cadherin-mediated synaptic recovery in the ischemic brain.
Diaz A, Merino P, McCann P, Yepes MA, Quiceno LG, Torre E, Tomkins A, Zhang X, Hales CM, Tong FC, Yepes M. Diaz A, et al. J Cereb Blood Flow Metab. 2021 Sep;41(9):2381-2394. doi: 10.1177/0271678X211002297. Epub 2021 Mar 24. J Cereb Blood Flow Metab. 2021. PMID: 33757316 Free PMC article. - Integrin alpha6 cleavage: a novel modification to modulate cell migration.
Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE. Pawar SC, et al. Exp Cell Res. 2007 Apr 1;313(6):1080-9. doi: 10.1016/j.yexcr.2007.01.006. Epub 2007 Jan 17. Exp Cell Res. 2007. PMID: 17303120 Free PMC article. - In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y, Zaias J, Duncan R, Russell SJ, Merchan JR. Jing Y, et al. Gene Ther. 2014 Mar;21(3):289-97. doi: 10.1038/gt.2013.84. Epub 2014 Jan 16. Gene Ther. 2014. PMID: 24430235 Free PMC article. - Endothelial-specific Enhancer as a Cis Element of PLAUR Regulation by TNF-alpha, IL-1beta, and VEGF.
Penkov D, Beloglazova I, Parfyonova Y. Penkov D, et al. Curr Pharm Des. 2024;30(21):1630-1640. doi: 10.2174/0113816128296376240424072322. Curr Pharm Des. 2024. PMID: 38715331 Review. - The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers.
Pyke C, Rømer J, Kallunki P, Lund LR, Ralfkiaer E, Danø K, Tryggvason K. Pyke C, et al. Am J Pathol. 1994 Oct;145(4):782-91. Am J Pathol. 1994. PMID: 7943170 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical